CTRI/2020/05/025286招募中不适用
A randomized, double-blind, placebo controlled clinical study to evaluate the efficacy and safety of the formulation for vitality, vigour, sexual well-being and improvement in quality of life in ageing males.
Sami Labs Limited2 个研究点 分布在 1 个国家目标入组 66 人开始时间: 2020年5月21日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 66
- 试验地点
- 2
- 主要终点
- 1 Improvement in psychological, somatic and sexual improvement through change in Aging Male’s Symptom Scale.
研究概览
简要总结
This proposed study is a randomized, double-blind, placebo-controlled trial, investigating the efficacy and safety of formulation (620 mg) for improvement in the symptoms associated with ageing like diminished vitality , vigour, erectile function and performance in comparison with placebo (620 mg) in men aged between 35-60 years. The improvement in symptoms will be analysed by the AMS scale; IIEF-5 score and associated serum bio-markers (testosterone & cortisol).
All the parameters will be assessed before and after treatment based on the specially prepared proforma. Appropriate test will be applied to the data outcome and discussion and conclusion will be made accordingly.
研究设计
- 研究类型
- Interventional
- 分配方式
- Computer generated randomization
- 盲法
- Participant and Investigator Blinded
入排标准
- 年龄范围
- 35.00 Year(s) 至 65.00 Year(s)（—）
- 性别
- Male
入选标准
- •1 Married male subjects of age ranging from 35-60 years with both years inclusive (minimum age being 35 years and maximum age being 60 years).
- •2 Complaints with symptoms of fatigue and diminished vitality with AMS questionnaire score ≥27 and ≤
- •3 Self-reported Mild to moderate Erectile problems with IIEF-5 score ≥12 and ≤ 21 with difficulty in maintaining erection or premature ejaculation.
- •4 The subjects must be in a marital relationship (Married), having stable monogamous sexual relationship with a female for a minimum of last 06 months and continue throughout till the end of the study.
- •5 Physically active and Planning to have regular sexual activity.
- •6 Commitment to comply with study protocol requirements.
- •7 Willing to sign informed consent.
排除标准
- •1 History of smoking, alcohol intake and narcotic/drug abuse within 3 months before Screening.
- •2 Subjects who want to lose weight or looking for weight loss program or significant lifestyle related modifications during the study.
- •3 History of surgical interventions or subjects with major psychiatric and neurological disorders such as Schizophrenia,Mental disorders, Alzheimer’s, Parkinsonism and Epilepsy, Multiple sclerosis etc.), major trauma or infections that are associated with the development of symptoms of ED and considered a potential cause of ED, severe systemic disorders including blood diseases and leukemias.
- •4 Having genital abnormalities or anatomical deformity of the penis including severe penile fibrosis or Peyronies disease or phimosis or any other condition which prevents normal sexual intercourse.
- •5 With blood pressure more than or equal to 140/85 mmHg and those who were on a “chronic use†for a minimum of 12 months or more of the following class of drugs viz Diuretics, Beta blockers and Calcium channel blockers.Subjects with blood pressure less than 140/85 and on monotherapy or low dose combination therapy without change in the dose from past 06 months need not be excluded.
- •6 Subjects with HbA1c ≥ 6.
- •7 Subjects with history of clinically significant thyroid disorder (hypo or hyper), gastrointestinal, cardiovascular, haematological, hepatic (SGOT or SGPT levels > 2 times Upper Limit of Normal),renal (serum creatinine ≥ 1.3 mg/dl),dialysis,respiratory or genitourinary abnormalities or diseases.
- •8 BMI > 30 Kg/m
- •9 Subjects detected with HIV and suffering from AIDS or on antiviral or anti-retroviral therapy.
- •10 Subjects with any clinically significant laboratory or ECG findings during screening.
- •11 Those subjects with Premature Ejaculation and organic impotence and clinically defined prostatitis and who have undergone pelvic surgery.
- •12 Subjects who are taking medications for erectile dysfunction, Phosphodiesterase Type-5 Inhibitors including sildenafil, tadalafil, vardenafil, avanafil must stop using these medications for at least 04 weeks before baseline visit.
- •13 Subjects those are not willing to stop taking the vitamins and supplements including herbal during the course of the study.
- •14 Subject who are allergic to herbal supplements and medications.
- •15 Subjects continuing tricyclic antidepressant and atypical antipsychotic drugs for the last 03 months.
- •16 Subject having participated in any clinical trial within last 03 months or any trial for testosterone boosting or ED,vigour,vitality, male sexual health and performance trials.
- •17 Subjects not ready to provide the identification proof i.e. Age and Gender,not ready to sign the consent and unable to comply with the protocol.
结局指标
主要结局
1 Improvement in psychological, somatic and sexual improvement through change in Aging Male’s Symptom Scale.
时间窗: 1 Aging Male’s Symptom Scale(Screening,Day30 and Day60). | 2 IIEF-5 questionnaire (Screening,Day30 and Day60).
2 Improvement in erectile function in comparison to placebo through Improvement in IIEF-5 questionnaire score.
时间窗: 1 Aging Male’s Symptom Scale(Screening,Day30 and Day60). | 2 IIEF-5 questionnaire (Screening,Day30 and Day60).
次要结局
- 1 Change in total and free blood Testosterone level in comparison with placebo.(2 Change in Salivary Cortisol level in comparison with placebo.)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Effectiveness and safety of a herbal composition to improve Aging Male SymptomsCTRI/2019/02/017506Laila Neutraceuticals Pvt Ltd120
已完成
2 期
Study of KaraShield-a herbal formulation towards the enhancement of immunity in healthy population.Upper Respiratory Tract InfectionsCTRI/2022/06/043331Green Chem120
已完成
2/3 期
A clinical study of KaraHeart for the management of cholesterol level in human participants.Preventative InterventionsCTRI/2020/07/026907GreenChem100
尚未招募
2 期
Evaluating the effect of Punarnavashtak Ghana and life style changes in Metabolic Associated Fatty Liver DiseaseFatty (change of) liver, not elsewhere classified. Ayurveda Condition: YAKRUDDALYUDARAH,CTRI/2025/04/084339DrDevkanya Khatediya68
已完成
3 期
A Study With SAGE-547 for Super-Refractory Status EpilepticusSuper-Refractory Status EpilepticusNCT02477618Supernus Pharmaceuticals, Inc.132